These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 20175815)

  • 1. Evaluation of inosin-5'-monophosphate dehydrogenase activity during maintenance therapy with tacrolimus.
    Maiguma T; Yosida T; Otsubo K; Okabe Y; Sugitani A; Tanaka M; Oishi R; Teshima D
    J Clin Pharm Ther; 2010 Feb; 35(1):79-85. PubMed ID: 20175815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and application of a high-performance liquid chromatography-based assay for determination of the activity of inosine 5'-monophosphate dehydrogenase in whole blood and isolated mononuclear cells.
    Albrecht W; Storck M; Pfetsch E; Martin W; Abendroth D
    Ther Drug Monit; 2000 Jun; 22(3):283-94. PubMed ID: 10850395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamic monitoring of mycophenolate mofetil.
    Budde K; Glander P; Bauer S; Braun K; Waiser J; Fritsche L; Mai I; Roots I; Neumayer HH
    Clin Chem Lab Med; 2000 Nov; 38(11):1213-6. PubMed ID: 11156363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inosine monophosphate dehydrogenase (IMPDH) activity as a pharmacodynamic biomarker of mycophenolic acid effects in pediatric kidney transplant recipients.
    Fukuda T; Goebel J; Thøgersen H; Maseck D; Cox S; Logan B; Sherbotie J; Seikaly M; Vinks AA
    J Clin Pharmacol; 2011 Mar; 51(3):309-20. PubMed ID: 20418509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of mycophenolate mofetil on IMP dehydrogenase after the first dose and after long-term treatment in renal transplant recipients.
    Glander P; Hambach P; Braun KP; Fritsche L; Waiser J; Mai I; Neumayer HH; Budde K
    Int J Clin Pharmacol Ther; 2003 Oct; 41(10):470-6. PubMed ID: 14703953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of inosine-monophosphate-dehydrogenase activity in patients with enteric-coated mycophenolate sodium or mycophenolate mofetil after renal transplantation.
    Rath T; Küpper M
    Transplant Proc; 2009; 41(6):2524-8. PubMed ID: 19715967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inosine monophosphate dehydrogenase variability in renal transplant patients on long-term mycophenolate mofetil therapy.
    Chiarelli LR; Molinaro M; Libetta C; Tinelli C; Cosmai L; Valentini G; Dal Canton A; Regazzi M
    Br J Clin Pharmacol; 2010 Jan; 69(1):38-50. PubMed ID: 20078611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamics of mycophenolic acid in stable renal transplant recipients treated with low doses of mycophenolate mofetil.
    Brunet M; Martorell J; Oppenheimer F; Vilardell J; Millán O; Carrillo M; Rojo I; Corbella J
    Transpl Int; 2000; 13 Suppl 1():S301-5. PubMed ID: 11112019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression in renal transplant recipients.
    Langman LJ; LeGatt DF; Halloran PF; Yatscoff RW
    Transplantation; 1996 Sep; 62(5):666-72. PubMed ID: 8830834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved assay for the nonradioactive determination of inosine 5'-monophosphate dehydrogenase activity in peripheral blood mononuclear cells.
    Glander P; Sombogaard F; Budde K; van Gelder T; Hambach P; Liefeldt L; Lorkowski C; Mai M; Neumayer HH; Vulto AG; Mathot RA
    Ther Drug Monit; 2009 Jun; 31(3):351-9. PubMed ID: 19333146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-radioactive determination of inosine 5'-monophosphate dehydro-genase (IMPDH) in peripheral mononuclear cells.
    Glander P; Braun KP; Hambach P; Bauer S; Mai I; Roots I; Waiser J; Fritsche L; Neumayer HH; Budde K
    Clin Biochem; 2001 Oct; 34(7):543-9. PubMed ID: 11738390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inosine monophosphate dehydrogenase activity in renal allograft recipients during mycophenolate treatment.
    Vethe NT; Mandla R; Line PD; Midtvedt K; Hartmann A; Bergan S
    Scand J Clin Lab Invest; 2006; 66(1):31-44. PubMed ID: 16464785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mycophenolic acid concentrations in peripheral blood mononuclear cells are associated with the incidence of rejection in renal transplant recipients.
    Md Dom ZI; Coller JK; Carroll RP; Tuke J; McWhinney BC; Somogyi AA; Sallustio BC
    Br J Clin Pharmacol; 2018 Oct; 84(10):2433-2442. PubMed ID: 29974488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study.
    Rissling O; Glander P; Hambach P; Mai M; Brakemeier S; Klonower D; Halleck F; Singer E; Schrezenmeier EV; Dürr M; Neumayer HH; Budde K
    Br J Clin Pharmacol; 2015 Nov; 80(5):1086-96. PubMed ID: 25913040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamic Monitoring of Mycophenolic Acid Therapy: Improved Liquid Chromatography-Tandem Mass Spectrometry Method for Measuring Inosin-5'-Monophosphate Dehydrogenase Activity.
    Weißbarth G; Wiesen MHJ; Fietz C; Streichert T; Ehren R; Weber LT; Müller C
    Ther Drug Monit; 2020 Apr; 42(2):282-288. PubMed ID: 31425491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of inosine monophosphate dehydrogenase type I and type II after mycophenolate mofetil treatment: a 2-year follow-up in kidney transplantation.
    Sanquer S; Maison P; Tomkiewicz C; Macquin-Mavier I; Legendre C; Barouki R; Lang P
    Clin Pharmacol Ther; 2008 Feb; 83(2):328-35. PubMed ID: 17713475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mycophenolic acid exposure and complement fraction C3 influence inosine 5'-monophosphate dehydrogenase activity in systemic lupus erythematosus.
    Mino Y; Naito T; Shimoyama K; Ogawa N; Kawakami J
    Ann Clin Biochem; 2017 Jul; 54(4):490-494. PubMed ID: 27538768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma and intracellular pharmacokinetic-pharmacodynamic analysis of mycophenolic acid in de novo kidney transplant patients.
    Thi MT; Mourad M; Capron A; Tshinanu FM; Vincent MF; Wallemacq P
    Clin Biochem; 2015 Apr; 48(6):401-5. PubMed ID: 25523299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Best single time points as surrogates to the tacrolimus and mycophenolic acid area under the curve in adult liver transplant patients beyond 12 months of transplantation.
    Mardigyan V; Tchervenkov J; Metrakos P; Barkun J; Deschenes M; Cantarovich M
    Clin Ther; 2005 Apr; 27(4):463-9. PubMed ID: 15922819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of IMPDH1 gene polymorphisms with subclinical acute rejection and mycophenolic acid exposure parameters on day 28 after renal transplantation.
    Kagaya H; Miura M; Saito M; Habuchi T; Satoh S
    Basic Clin Pharmacol Toxicol; 2010 Aug; 107(2):631-6. PubMed ID: 20136638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.